Posted: 21 August 2023

Closes: 6 October 2023

CUREator+ is a partnership between Brandon BioCatalyst and ANDHealth. Selected by the Federal Government’s Medical Research Future Fund (MRFF) through a competitive process,

CUREator+ will deliver the $50 million MRFF BioMedTech Incubator (BMTI) program to medical research and medical innovation projects with commercial potential. CUREator+ brings together the experience of the Partners and their respective MRFF Early-Stage Translation and Commercialisation Support (ESTAC) programs, CUREator and ANDHealth+. 

CUREator+ is a national program focused on accelerating the research translation and commercialisation of preclinical and clinical early-stage Australian medical research and medical innovations with commercial potential. These innovations include drugs (novel and repurposed), devices, diagnostics and digital technologies that address an unmet need, demonstrate a clear clinical and commercial differentiation, and are underpinned by strong intellectual property positions. It is expected that projects applying for CUREator+ funding possess a lead asset(s)/product/technology, which has demonstrated Proof of Concept/ Proof of Principle to support their funding request. 

CUREator+ will provide small-to-medium enterprises (SMEs) with access to investment capital, commercial guidance, international expert networks, and hands-on support and mentorship to drive the translation and commercialisation of their opportunities. In addition to program oversight, SMEs will be supported to secure follow-on funding and facilitate their continued development. 

CUREator+ will provide funding up to a maximum of $5 million per project in two funding stages.  

Stage 1: Funding available between $1 million to $2.5 million. Funding will be provided in tranches and aligned to commercially relevant milestones. Successful projects will have up to 2 years to complete project activities and achievement of milestones, agreed as part of the application process. 

Stage 2: Top-up funding will be available on a competitive basis to successful companies (maximum total of $5 million in grant funding per project from Stage 1 and 2) who meet their milestones during the Stage 1 period. Successful projects will have a maximum total of 4 years to complete Stage 1 and 2 project activities and achievement of milestones. 

Funding round open 

CUREator+ Funding will be available through a competitive process and delivered in two funding rounds.  

The first round is now open for Expression of Interest (EOI) applications and will close on 6 October 2023 at 5pm AEDT. A second funding round will open in mid-2024.  

Interested researchers and biotech companies are invited to apply via:

Please refer to the funding guidelines and FAQs for further details available here.  

For more information on CUREator+: 

CUREator+ will host a national webinar and encourages provide prospective applicants to book a 30-minute meeting with the CUREator+ team to discuss their opportunity.    

The webinar will be held on Wednesday 30th August at 12pm AEST.  To register for the webinar visit: or  

To arrange a meeting to discuss any opportunities related to drugs, devices and diagnostics or general enquiries, please contact the CUREator team at: 

To arrange a meeting to discuss any opportunity related to digital and connected health innovations or general enquiries, please contact the ANDHealth team at 

You can download the FAQ’s and guidelines here.


News & opinion

Member Directory